Core Framework & Diagram The Future of Immunotherapy

Treating right after surgery, when tumor burden is lowest — instead of waiting for advanced disease — already cut recurrence risk 44% in one major trial.

Combining therapies that each unblock a different bottleneck — a vaccine plus a checkpoint inhibitor, or a cell therapy plus a tumor-opening virus — instead of relying on one drug alone.

Moving from simply ‘releasing the brakes’ to precisely directing which cells act where, and building in an emergency stop for when things go too far.

Moving from broad cancer-type categories to each patient’s actual immune fingerprint — to select the one combination most likely to work for them specifically.

Manufacturing therapies once instead of individually, or delivering them by a single injection instead of weeks of lab work, could cut costs by 10–100×.